Vanguard Group Inc Fate Therapeutics Inc Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 10,333,033 shares of FATE stock, worth $16 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,333,033
Previous 10,404,123
0.68%
Holding current value
$16 Million
Previous $36.4 Million
53.18%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding FATE
# of Institutions
167Shares Held
101MCall Options Held
41.3KPut Options Held
15.9K-
Redmile Group, LLC San Francisco, CA12.9MShares$20 Million1.66% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$15.7 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.84MShares$7.5 Million0.16% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.38MShares$6.79 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.56MShares$5.51 Million0.15% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $150M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...